HRP20120058T1 - Postupci i spojevi za pripremu analoga cc-1065 - Google Patents
Postupci i spojevi za pripremu analoga cc-1065 Download PDFInfo
- Publication number
- HRP20120058T1 HRP20120058T1 HR20120058T HRP20120058T HRP20120058T1 HR P20120058 T1 HRP20120058 T1 HR P20120058T1 HR 20120058 T HR20120058 T HR 20120058T HR P20120058 T HRP20120058 T HR P20120058T HR P20120058 T1 HRP20120058 T1 HR P20120058T1
- Authority
- HR
- Croatia
- Prior art keywords
- substituted
- unsubstituted
- alkyl
- compound
- group
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract 21
- 150000001875 compounds Chemical class 0.000 title claims abstract 17
- 125000000217 alkyl group Chemical group 0.000 claims abstract 18
- 125000000547 substituted alkyl group Chemical group 0.000 claims abstract 12
- 125000006239 protecting group Chemical group 0.000 claims abstract 10
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract 8
- 125000003118 aryl group Chemical group 0.000 claims abstract 8
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract 8
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims abstract 8
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 7
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract 6
- 230000029936 alkylation Effects 0.000 claims abstract 5
- 238000005804 alkylation reaction Methods 0.000 claims abstract 5
- 125000003107 substituted aryl group Chemical group 0.000 claims abstract 5
- 125000003545 alkoxy group Chemical group 0.000 claims abstract 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract 3
- 229910052736 halogen Inorganic materials 0.000 claims abstract 3
- 125000005843 halogen group Chemical group 0.000 claims abstract 3
- 238000006798 ring closing metathesis reaction Methods 0.000 claims abstract 3
- 150000003839 salts Chemical class 0.000 claims abstract 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims abstract 2
- -1 amine compound Chemical class 0.000 claims 15
- 125000004404 heteroalkyl group Chemical group 0.000 claims 8
- 230000015572 biosynthetic process Effects 0.000 claims 6
- 150000001412 amines Chemical group 0.000 claims 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 2
- 125000002252 acyl group Chemical group 0.000 claims 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 230000026045 iodination Effects 0.000 claims 2
- 238000006192 iodination reaction Methods 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 125000001151 peptidyl group Chemical group 0.000 claims 2
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 101001043818 Mus musculus Interleukin-31 receptor subunit alpha Proteins 0.000 claims 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 claims 1
- 101100212791 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) YBL068W-A gene Proteins 0.000 claims 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 claims 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims 1
- LHHCSNFAOIFYRV-DOVBMPENSA-N boceprevir Chemical compound O=C([C@@H]1[C@@H]2[C@@H](C2(C)C)CN1C(=O)[C@@H](NC(=O)NC(C)(C)C)C(C)(C)C)NC(C(=O)C(N)=O)CC1CCC1 LHHCSNFAOIFYRV-DOVBMPENSA-N 0.000 claims 1
- ROORDVPLFPIABK-UHFFFAOYSA-N diphenyl carbonate Chemical group C=1C=CC=CC=1OC(=O)OC1=CC=CC=C1 ROORDVPLFPIABK-UHFFFAOYSA-N 0.000 claims 1
- 239000001177 diphosphate Substances 0.000 claims 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical class [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 claims 1
- 235000011180 diphosphates Nutrition 0.000 claims 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 125000005544 phthalimido group Chemical group 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical group C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 claims 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 125000000025 triisopropylsilyl group Chemical group C(C)(C)[Si](C(C)C)(C(C)C)* 0.000 claims 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 239000001226 triphosphate Substances 0.000 claims 1
- 235000011178 triphosphate Nutrition 0.000 claims 1
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/58—[b]- or [c]-condensed
- C07D209/60—Naphtho [b] pyrroles; Hydrogenated naphtho [b] pyrroles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Indole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Saccharide Compounds (AREA)
- Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
Postupak za pripremu spoja (I) ili njegove soli, pri čemu su i R1 i R2 nezavisno H, supstituirani alkil ili nesupstituirani alkil, -C(O)OR', -C(O)NR'R", ili zaštitna grupa, gdje su R' i R" nezavisno izabrani iz grupe koju čine H, supstituirani alkil, nesupstituirani alkil, supstituirani aril, nesupstituirani aril, supstituirani heteroaril, nesupstituirani heteroaril, supstituirani heterocikloalkil i nesupstituirani heterocikloalkil, R6 je H, supstituirani C1-6 alkil ili nesupstituirani C1-6 alkil, cijano ili alkoksi; i X je halogen, pri čemu taj postupak sadrži: dodavanje zaštitnih grupa R1' i R2' spoju (II) da bi se formirao spoj (III) gdje, R3 je supstituirani alkil ili nesupstituirani alkil; istvaranje peto-članog prstena koji sadrži dušik spoja (III) alkilacijom aril prstena pored dušika, nakon čega slijedi zatvaranje prstena. Patent sadrži još 15 patentnih zahtjeva.
Claims (16)
1. Postupak za pripremu spoja (I) ili njegove soli,
[image]
pri čemu su i R1 i R2 nezavisno H, supstituirani alkil ili nesupstituirani alkil, -C(O)OR', -C(O)NR'R", ili zaštitna grupa, gdje su R' i R" nezavisno izabrani iz grupe koju čine H, supstituirani alkil, nesupstituirani alkil, supstituirani aril, nesupstituirani aril, supstituirani heteroaril, nesupstituirani heteroaril, supstituirani heterocikloalkil i nesupstituirani heterocikloalkil, R6 je H, supstituirani C1-6 alkil ili nesupstituirani C1-6 alkil, cijano ili alkoksi; i X je halogen, pri čemu taj postupak sadrži:
dodavanje zaštitnih grupa R1' i R2' spoju (II)
[image]
da bi se formirao spoj (III)
[image]
gdje, R3 je supstituirani alkil ili nesupstituirani alkil; i
stvaranje peto-članog prstena koji sadrži dušik spoja (III) alkilacijom aril prstena pored dušika, nakon čega slijedi zatvaranje prstena.
2. Postupak prema patentnom zahtjevu 1, gdje, R3 je metil.
3. Postupak prema patentnom zahtjevu 1, gdje, X je Cl ili Br.
4. Postupak prema patentnom zahtjevu 3, gdje, X je Br.
5. Postupak prema patentnom zahtjevu 1, gdje, R1' i R2' su različite zaštitne grupe.
6. Postupak prema patentnom zahtjevu 5, gdje, dodavanje R1' i R2' sadrži dodavanje R1' spoju (II) da bi se formiralo spoj (III')
[image]
i zamijenu zaštitne grupe R1' na hidroksil supstituentu zaštitnom grupom R2'.
7. Postupak prema patentnom zahtjevu 5, gdje, R1' je terc-butiloksikarbonil.
8. Postupak prema patentnom zahtjevu 7, gdje, R2' je -CH2Ph.
9. Postupak prema patentnom zahtjevu 1, gdje su R1' i R2' isti.
10. Postupak prema patentnom zahtjevu 1, koji dalje sadrži zamjenu R1' i R2' vodikom poslije stvaranja peto-članog prstena.
11. Postupak prema patentnom zahtjevu 1, gdje su R1' i R1 isti i R2' i R2 su isti.
12. Postupak prema patentnom zahtjevu 1, gdje stvaranje peto-članog prstena sadrži jodiranje ugljika pored amin supstituenta spoja (III), nakon čega slijedi alkilacija primjenom 1,3-dihalopropena.
13. Postupak za pripremu CBI analoga CC-1065 ili njegove farmaceutski prihvatljive soli, koji ima slijedeću formulu:
[image]
gdje, X je halo;
svako X1 i Z su nezavisno izabrani od O, S i NR8, gdje je R8 član izabran iz grupe koju čine H, supstituirani alkil ili nesupstituirani alkil, supstituirani heteroalkil ili nesupstituirani heteroalkil, i acil;
R4 , R4', R5 i R5, su članovi nezavisno izabrani iz grupe koju čine H, supstituirani alkil, nesupstituirani alkil, supstituirani aril, nesupstituirani aril, supstituirani heteroaril, nesupstituirani heteroaril, supstituirani heterocikloalkil, nesupstituirani heterocikloalkil, halogen, NO2, NR9R10, NC(O)R9, OC(O)NR9R10, OC(O)OR9, C(O)R9, SR9, OR9 i CR9=NR10,
gdje su R9 i R10 nezavisno izabrani iz grupe koju čine H, supstituirani alkil ili nesupstituirani alkil, supstituirani heteroalkil ili nesupstituirani heteroalkil, supstituirani aril ili nesupstituirani aril, supstituirani heteroaril ili nesupstituirani heteroaril, supstituirani heterocikloalkil ili nesupstituirani heterocikloalkil, i supstituirani peptidil ili nesupstituirani peptidil, ili gdje, R9 i R10 zajedno sa atomom dušika za koji su vezani, izborno su spojeni tako da formiraju supstituirani ili nesupstituirani heterocikloalkil sustav prstena koji ima od 4 do 6 članova, koji izborno sadrži dva ili više heteroatoma, i
svako R11 i R11' nezavisno su H, supstituirani C1-6 alkil ili nesupstituirani C1-6 alkil;
R6 je H, supstituirani C1-6 alkil ili nesupstituirani C1-6 alkil, cijano ili alkoksi; i R7 je član izabran iz grupe koju čine H, supstituirani alkil, nesupstituirani alkil, supstituirani heteroalkil, nesupstituirani heteroalkil, difosfati, trifosfati, acil, C(O)R12R13, C(Q)OR12, C(O)NR12R13, P(O)(OR12)(O)CHR12R13, SR12 i SiR12R13R14,
gdje su R12, R13 i R14 članovi nezavisno izabrani iz grupe koju čine H, supstituirani alkil ili nesupstituirani alkil, supstituirani heteroalkil ili nesupstituirani heteroalkil i supstituirani aril ili nesupstituirani aril, ili gdje, R12 i R13 zajedno sa atomom dušika za koji su vezani, izborno su spojeni tako da formiraju supstituirani ili nesupstituirani heterocikloalkil sustav prstena koji ima od 4 do 6 članova, koji izborno sadrži dva ili više heteroatoma;
pri čemu taj postupak sadrži:
dodavanje zaštitnih grupa R1' i R2' spoju (II)
[image]
da bi se formirao spoj (III)
[image]
gdje je R3 supstituirani alkil ili nesupstituirani alkil;
stvaranje peto-članog prstena koji sadrži dušik amina spoja (III) alkilacijom aril prstena pored dušika, nakon čega slijedi zatvaranje prstena; i
dodavanje vezujuće jedinice spoju (III), uklanjanjem zaštitne grupe R1' i vezivanjem grupe:
[image]
za amin supstituent spoja (III), gdje
[image]
označava točku na kojoj je grupa vezana za amin supstituent.
14. Postupak prema patentnom zahtjevu 13, gdje stvaranje peto-članog prstena sadrži jodiranje ugljika pored amin supstituenta spoja (III), nakon čega slijedi alkilacija primjenom 1,3-dihalopropena prije stvaranja peto-članog prstena.
15. Postupak prema patentnom zahtjevu 13, gdje, R6 je H.
16. Postupak prema patentnom zahtjevu 13, pri čemu su zaštitne grupe R1' i R2' izabrane iz grupe koju čine: BOC, FMOC, 2-trimetbilsililetoksikarbonil, aliloksikarbonil, 4-metil-1-piperazinkarbonil, 1-metil-1-(4-bifenilil)etoksikarbonil, difeniloksikarbonil, benzil, t-butil, tetrahidropiran, trimetilsilil, t-butildimetilsilil, triizopropilsilil, t-butildifenilsilil, 2,2,2-trihloroetil oksikarbonil, diizopropilmetil oksikarbonil, vinil oksikarbonil, metoksi benzil oksikarbonil, nitrobenziloksikarbonil, cikloheksil oksikarbonil, ciklopentil oksikarbonil, formil, acetil, trihaloacetil, benzoil, nitrofenilacetil, 2-nitrobenzensulfonil, ftalimido i ditiasukcinoil.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US73080405P | 2005-10-26 | 2005-10-26 | |
| PCT/US2006/060050 WO2007051081A1 (en) | 2005-10-26 | 2006-10-18 | Methods and compounds for preparing cc-1065 analogs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20120058T1 true HRP20120058T1 (hr) | 2012-02-29 |
Family
ID=37766648
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20120058T HRP20120058T1 (hr) | 2005-10-26 | 2012-01-19 | Postupci i spojevi za pripremu analoga cc-1065 |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US7847105B2 (hr) |
| EP (1) | EP1940789B1 (hr) |
| JP (1) | JP5116686B2 (hr) |
| KR (1) | KR20080068084A (hr) |
| CN (1) | CN101365679B (hr) |
| AT (1) | ATE534629T1 (hr) |
| AU (1) | AU2006305842B2 (hr) |
| BR (1) | BRPI0619331A2 (hr) |
| CA (1) | CA2627046C (hr) |
| CY (1) | CY1112533T1 (hr) |
| DK (1) | DK1940789T3 (hr) |
| EA (1) | EA015324B1 (hr) |
| ES (1) | ES2375843T3 (hr) |
| HK (1) | HK1118549A1 (hr) |
| HR (1) | HRP20120058T1 (hr) |
| IL (1) | IL190971A (hr) |
| NO (1) | NO20082243L (hr) |
| PL (1) | PL1940789T3 (hr) |
| PT (1) | PT1940789E (hr) |
| RS (1) | RS52100B (hr) |
| SI (1) | SI1940789T1 (hr) |
| WO (1) | WO2007051081A1 (hr) |
| ZA (1) | ZA200804521B (hr) |
Families Citing this family (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2447139C (en) | 2001-05-11 | 2013-11-19 | Ludwig Institute For Cancer Research | Specific binding proteins and uses thereof |
| US20100056762A1 (en) | 2001-05-11 | 2010-03-04 | Old Lloyd J | Specific binding proteins and uses thereof |
| NZ566395A (en) | 2005-09-26 | 2012-03-30 | Medarex Inc | Human monoclonal antibodies to CD70 |
| CN104013956B (zh) | 2007-01-25 | 2018-12-18 | 达娜-法勃肿瘤研究所公司 | 抗egfr抗体在治疗egfr突变体介导的疾病中的用途 |
| JP5618549B2 (ja) | 2007-03-15 | 2014-11-05 | ルードヴィッヒ インスティテュート フォー キャンサーリサーチ リミテッド | Ｅｇｆｒ抗体及びｓｒｃ阻害剤を用いる治療方法及び関連製剤 |
| US9901567B2 (en) | 2007-08-01 | 2018-02-27 | Syntarga B.V. | Substituted CC-1065 analogs and their conjugates |
| ES2609915T3 (es) | 2007-08-14 | 2017-04-25 | Ludwig Institute For Cancer Research Ltd. | Anticuerpo monoclonal 175 direccionado al receptor de EGF y derivados y usos del mismo |
| WO2009026274A1 (en) | 2007-08-22 | 2009-02-26 | Medarex, Inc. | Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions |
| MX2010003581A (es) * | 2007-10-01 | 2010-08-02 | Bristol Myers Squibb Co | Anticuerpos humanos que se adhieren a mesotelina, y usos de los mismos. |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| BRPI0921687A8 (pt) | 2008-11-03 | 2022-11-08 | Syntarga Bv | Composto , conjugado , uso de um composto , composição farmacêutica, processo para preparar uma composição famacêutica , método para tratar um mamífero em necessidade do mesmo ,e, método para tratar ou prevenir um tumor em um mamífero. |
| WO2010096394A2 (en) | 2009-02-17 | 2010-08-26 | Redwood Biosciences, Inc. | Aldehyde-tagged protein-based drug carriers and methods of use |
| ES2639026T3 (es) | 2009-03-05 | 2017-10-25 | Oxford Biotherapeutics Ltd. | Anticuerpos totalmente humanos específicos para CADM1 |
| US8394922B2 (en) | 2009-08-03 | 2013-03-12 | Medarex, Inc. | Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof |
| PL3056203T3 (pl) * | 2010-04-21 | 2018-06-29 | Syntarga B.V. | Koniugaty analogów CC-1065 i łączników dwufunkcyjnych |
| US8956859B1 (en) | 2010-08-13 | 2015-02-17 | Aviex Technologies Llc | Compositions and methods for determining successful immunization by one or more vaccines |
| JOP20210044A1 (ar) | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
| JP6162606B2 (ja) | 2011-01-14 | 2017-07-12 | レッドウッド バイオサイエンス， インコーポレイテッド | アルデヒド−タグ付き免疫グロブリンポリペプチド及びその使用方法 |
| JP6113194B2 (ja) | 2012-02-13 | 2017-04-12 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | エンジイン化合物、その抱合体、ならびにその使用および方法 |
| UY34887A (es) | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
| EA030830B1 (ru) | 2013-02-14 | 2018-10-31 | Бристол-Майерс Сквибб Компани | Соединения тубулизина, способы их получения и применение |
| PT3092010T (pt) | 2014-01-10 | 2018-09-28 | Synthon Biopharmaceuticals Bv | Método para purificação de conjugados anticorpo-fármaco ligados por cys |
| KR20220045075A (ko) | 2014-01-10 | 2022-04-12 | 비온디스 비.브이. | 자궁내막암의 치료에서 사용하기 위한 듀오카르마이신 adc |
| KR102344354B1 (ko) | 2014-01-10 | 2021-12-28 | 비온디스 비.브이. | 향상된 생체내 항종양 활성을 나타내는 듀오카르마이신 adc |
| AU2015231210B2 (en) | 2014-03-20 | 2019-09-12 | Bristol-Myers Squibb Company | Stabilized fibronectin based scaffold molecules |
| EA037006B1 (ru) | 2014-06-06 | 2021-01-26 | Бристол-Майерс Сквибб Компани | Антитела к индуцируемому глюкокортикоидами рецептору фактора некроза опухолей (gitr) и их применения |
| US10077287B2 (en) | 2014-11-10 | 2018-09-18 | Bristol-Myers Squibb Company | Tubulysin analogs and methods of making and use |
| CN107250157B (zh) | 2014-11-21 | 2021-06-29 | 百时美施贵宝公司 | 包含修饰的重链恒定区的抗体 |
| ME03806B (me) | 2014-11-21 | 2021-04-20 | Bristol Myers Squibb Co | Antitela protiv cd73 i njihova upotreba |
| ES2941895T3 (es) | 2014-11-25 | 2023-05-26 | Bristol Myers Squibb Co | Métodos y composiciones para radioetiquetado con 18F del dominio de fibronectina tipo (III) |
| ES2822990T3 (es) | 2014-11-25 | 2021-05-05 | Bristol Myers Squibb Co | Novedosos polipéptidos de unión a PD-L1 para obtención de imágenes |
| CA2971542A1 (en) | 2014-12-19 | 2016-06-23 | Regenesance B.V. | Antibodies that bind human c6 and uses thereof |
| CN107231804B (zh) | 2015-01-14 | 2019-11-26 | 百时美施贵宝公司 | 亚杂芳基桥连苯并二氮杂*二聚体、其缀合物及制备和使用方法 |
| KR20180057657A (ko) | 2015-09-23 | 2018-05-30 | 브리스톨-마이어스 스큅 컴퍼니 | 글리피칸-3-결합 피브로넥틴 기반 스캐폴드 분자 |
| ES2926969T3 (es) | 2015-11-19 | 2022-10-31 | Bristol Myers Squibb Co | Anticuerpos contra el receptor de factor de necrosis de tumor inducido por glucocorticoides (gitr) y usos de los mismos |
| IL295230A (en) | 2016-03-04 | 2022-10-01 | Bristol Myers Squibb Co | Combination therapy with anti-cd73 antibodies |
| WO2017189432A1 (en) | 2016-04-26 | 2017-11-02 | R.P. Scherer Technologies, Llc | Antibody conjugates and methods of making and using the same |
| WO2017210335A1 (en) | 2016-06-01 | 2017-12-07 | Bristol-Myers Squibb Company | Imaging methods using 18f-radiolabeled biologics |
| JP7016323B2 (ja) | 2016-06-01 | 2022-02-21 | ブリストル－マイヤーズ スクイブ カンパニー | Ｐｄ－ｌ１結合ポリペプチドを用いるｐｅｔ造影 |
| UY37325A (es) | 2016-07-14 | 2018-01-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Anticuerpos monoclonales que se enlazan a tim3 para estimular respuestas inmunitarias y composiciones que los contienen |
| KR102493853B1 (ko) | 2016-08-19 | 2023-01-30 | 브리스톨-마이어스 스큅 컴퍼니 | 세코-시클로프로파피롤로인돌 화합물, 그의 항체-약물 접합체, 및 제조 및 사용 방법 |
| US10398783B2 (en) | 2016-10-20 | 2019-09-03 | Bristol-Myers Squibb Company | Antiproliferative compounds and conjugates made therefrom |
| KR102573778B1 (ko) | 2017-02-17 | 2023-08-31 | 브리스톨-마이어스 스큅 컴퍼니 | 알파-시뉴클레인에 대한 항체 및 그의 용도 |
| US11339218B2 (en) | 2017-05-10 | 2022-05-24 | Zhejiang Shimai Pharmaceutical Co., Ltd. | Human monoclonal antibodies against LAG3 and uses thereof |
| MX2019013132A (es) | 2017-05-25 | 2020-01-27 | Bristol Myers Squibb Co | Anticuerpos que comprenden regiones constantes pesadas modificadas. |
| US10472361B2 (en) | 2017-08-16 | 2019-11-12 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a benzotriazole moiety, conjugates thereof, and methods and uses therefor |
| US10494370B2 (en) | 2017-08-16 | 2019-12-03 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a pyridine or pyrazine moiety, conjugates thereof, and methods and uses therefor |
| US10508115B2 (en) | 2017-08-16 | 2019-12-17 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor |
| US10457681B2 (en) | 2017-08-16 | 2019-10-29 | Bristol_Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a tricyclic moiety, conjugates thereof, and methods and uses therefor |
| US10487084B2 (en) | 2017-08-16 | 2019-11-26 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a heterobiaryl moiety, conjugates thereof, and methods and uses therefor |
| EP3694552A1 (en) | 2017-10-10 | 2020-08-19 | Tilos Therapeutics, Inc. | Anti-lap antibodies and uses thereof |
| JP7358361B2 (ja) | 2018-01-12 | 2023-10-10 | ブリストル－マイヤーズ スクイブ カンパニー | Ｔｉｍ３に対する抗体およびその使用 |
| TW202003565A (zh) | 2018-03-23 | 2020-01-16 | 美商必治妥美雅史谷比公司 | 抗mica及/或micb抗體及其用途 |
| MX2020010204A (es) | 2018-04-02 | 2021-01-29 | Bristol Myers Squibb Co | Anticuerpos anti-trem-1 y usos de los mismos. |
| WO2019209811A1 (en) | 2018-04-24 | 2019-10-31 | Bristol-Myers Squibb Company | Macrocyclic toll-like receptor 7 (tlr7) agonists |
| MX2020013923A (es) | 2018-06-29 | 2021-03-29 | Apitbio Inc | Anticuerpos anti molécula de adhesión celular l1 (l1cam) y usos de estos. |
| US11554120B2 (en) | 2018-08-03 | 2023-01-17 | Bristol-Myers Squibb Company | 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor |
| US11130802B2 (en) | 2018-10-10 | 2021-09-28 | Tilos Therapeutics, Inc. | Anti-lap antibody variants |
| JP2022513653A (ja) | 2018-11-28 | 2022-02-09 | ブリストル－マイヤーズ スクイブ カンパニー | 修飾された重鎖定常領域を含む抗体 |
| US20210403602A1 (en) | 2018-12-03 | 2021-12-30 | Bristol-Myers Squibb Company | Anti-ido antibody and uses thereof |
| CN109762067B (zh) | 2019-01-17 | 2020-02-28 | 北京天广实生物技术股份有限公司 | 结合人Claudin 18.2的抗体及其用途 |
| WO2020154293A1 (en) | 2019-01-22 | 2020-07-30 | Bristol-Myers Squibb Company | Antibodies against il-7r alpha subunit and uses thereof |
| WO2021011678A1 (en) | 2019-07-15 | 2021-01-21 | Bristol-Myers Squibb Company | Anti-trem-1 antibodies and uses thereof |
| WO2021011681A1 (en) | 2019-07-15 | 2021-01-21 | Bristol-Myers Squibb Company | Antibodies against human trem-1 and uses thereof |
| US20230057939A1 (en) | 2020-01-13 | 2023-02-23 | Neoimmunetech, Inc. | Method of treating a tumor with a combination of il-7 protein and a bispecific antibody |
| WO2021170020A1 (en) | 2020-02-27 | 2021-09-02 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Antibodies binding il4r and uses thereof |
| EP4132971A1 (en) | 2020-04-09 | 2023-02-15 | Merck Sharp & Dohme LLC | Affinity matured anti-lap antibodies and uses thereof |
| CN114685669A (zh) | 2020-12-30 | 2022-07-01 | 和铂医药(苏州)有限公司 | 结合trop2的抗体及其用途 |
| WO2022212876A1 (en) | 2021-04-02 | 2022-10-06 | The Regents Of The University Of California | Antibodies against cleaved cdcp1 and uses thereof |
| AU2022364888A1 (en) | 2021-10-14 | 2024-05-30 | Latticon (Suzhou) Biopharmaceuticals Co., Ltd. | Novel antibody-cytokine fusion protein, preparation method therefor and use thereof |
Family Cites Families (106)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4169888A (en) | 1977-10-17 | 1979-10-02 | The Upjohn Company | Composition of matter and process |
| US4391904A (en) | 1979-12-26 | 1983-07-05 | Syva Company | Test strip kits in immunoassays and compositions therein |
| US4671958A (en) | 1982-03-09 | 1987-06-09 | Cytogen Corporation | Antibody conjugates for the delivery of compounds to target sites |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4912227A (en) | 1984-02-21 | 1990-03-27 | The Upjohn Company | 1,2,8,8A-tetrahydrocyclopropa(c)pyrrolo(3,2-e)-indol-4-(5H)-ones and related compounds |
| US4978757A (en) | 1984-02-21 | 1990-12-18 | The Upjohn Company | 1,2,8,8a-tetrahydrocyclopropa (C) pyrrolo [3,2-e)]-indol-4(5H)-ones and related compounds |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| WO1987006265A1 (en) | 1986-04-17 | 1987-10-22 | Kyowa Hakko Kogyo Co., Ltd. | Novel compounds dc-88a and dc-89a1 and process for their preparation |
| US5332837A (en) | 1986-12-19 | 1994-07-26 | The Upjohn Company | CC-1065 analogs |
| US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
| US5773435A (en) | 1987-08-04 | 1998-06-30 | Bristol-Myers Squibb Company | Prodrugs for β-lactamase and uses thereof |
| US4952394A (en) | 1987-11-23 | 1990-08-28 | Bristol-Myers Company | Drug-monoclonal antibody conjugates |
| US4994578A (en) | 1987-11-27 | 1991-02-19 | Meiji Seika Kaisha, Ltd. | Certain anti-tumor duocarmycin antibiotics from streptomyces |
| US5147786A (en) | 1988-04-22 | 1992-09-15 | Monsanto Company | Immunoassay for the detection of α-haloacetamides |
| JP2642165B2 (ja) | 1988-07-22 | 1997-08-20 | 協和醗酵工業株式会社 | 新規ｄｃ−８９化合物およびその製造法 |
| US5084468A (en) | 1988-08-11 | 1992-01-28 | Kyowa Hakko Kogyo Co., Ltd. | Dc-88a derivatives |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5176996A (en) | 1988-12-20 | 1993-01-05 | Baylor College Of Medicine | Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use |
| JP2598116B2 (ja) | 1988-12-28 | 1997-04-09 | 協和醗酵工業株式会社 | 新規物質ｄｃ１１３ |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| JP2510335B2 (ja) | 1989-07-03 | 1996-06-26 | 協和醗酵工業株式会社 | Ｄｃ―８８ａ誘導体 |
| US5187186A (en) | 1989-07-03 | 1993-02-16 | Kyowa Hakko Kogyo Co., Ltd. | Pyrroloindole derivatives |
| US5495009A (en) | 1989-10-24 | 1996-02-27 | Gilead Sciences, Inc. | Oligonucleotide analogs containing thioformacetal linkages |
| US5334528A (en) | 1989-10-30 | 1994-08-02 | The Regents Of The University Of California | Monoclonal antibodies to cyclodiene insecticides and method for detecting the same |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| JP3068180B2 (ja) | 1990-01-12 | 2000-07-24 | アブジェニックス インコーポレイテッド | 異種抗体の生成 |
| WO1991016324A1 (en) | 1990-04-25 | 1991-10-31 | The Upjohn Company | Novel cc-1065 analogs |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| US5137877B1 (en) | 1990-05-14 | 1996-01-30 | Bristol Myers Squibb Co | Bifunctional linking compounds conjugates and methods for their production |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| EP0468400B1 (en) | 1990-07-26 | 1996-08-14 | Kyowa Hakko Kogyo Co., Ltd. | DC-89 derivatives as antitumoral agents |
| GB9017024D0 (en) | 1990-08-03 | 1990-09-19 | Erba Carlo Spa | New linker for bioactive agents |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| ATE158021T1 (de) | 1990-08-29 | 1997-09-15 | Genpharm Int | Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| JPH0597853A (ja) | 1991-10-07 | 1993-04-20 | Kyowa Hakko Kogyo Co Ltd | Ｄｃ−８９誘導体の臭化水素酸塩 |
| PT1024191E (pt) | 1991-12-02 | 2008-12-22 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
| US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
| EP0563475B1 (en) | 1992-03-25 | 2000-05-31 | Immunogen Inc | Cell binding agent conjugates of derivatives of CC-1065 |
| GB9314960D0 (en) | 1992-07-23 | 1993-09-01 | Zeneca Ltd | Chemical compounds |
| JP3514490B2 (ja) | 1992-08-21 | 2004-03-31 | 杏林製薬株式会社 | トリフルオロメチルピロロインドールカルボン酸エステル誘導体及びその製造方法 |
| US5288514A (en) | 1992-09-14 | 1994-02-22 | The Regents Of The University Of California | Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support |
| US5324483B1 (en) | 1992-10-08 | 1996-09-24 | Warner Lambert Co | Apparatus for multiple simultaneous synthesis |
| DE4314091A1 (de) | 1993-04-29 | 1994-11-03 | Boehringer Mannheim Gmbh | Immunologisches Nachweisverfahren für Triazine |
| US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| US5786377A (en) | 1993-11-19 | 1998-07-28 | Universidad De Santiago De Compostela | Pyrrolo 3,2-E!indol derivatives, process for the preparation thereof and applications |
| DE69533277T2 (de) | 1994-04-22 | 2005-07-21 | Kyowa Hakko Kogyo Co., Ltd. | Dc-89 derivat |
| JPH07309761A (ja) | 1994-05-20 | 1995-11-28 | Kyowa Hakko Kogyo Co Ltd | デュオカルマイシン誘導体の安定化法 |
| US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
| CA2203622C (en) | 1994-08-19 | 2011-11-01 | Andre Trouet | Compounds, pharmaceutical composition and diagnostic device comprising them and their use |
| CA2201097A1 (en) | 1994-09-30 | 1996-04-11 | Kyowa Hakko Kogyo Co., Ltd. | Anti-tumor agents |
| AU693283B2 (en) | 1994-11-29 | 1998-06-25 | Kyorin Pharmaceutical Co. Ltd. | Acrylamide derivatives and process for producing the same |
| JP3871713B2 (ja) | 1995-05-10 | 2007-01-24 | 協和醗酵工業株式会社 | 新規毒素複合体 |
| US5686237A (en) | 1995-06-05 | 1997-11-11 | Al-Bayati; Mohammed A. S. | Use of biomarkers in saliva to evaluate the toxicity of agents and the function of tissues in both biomedical and environmental applications |
| US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
| US5646298A (en) * | 1995-06-07 | 1997-07-08 | Procoron, Inc. | Cyclopropylindole prodrugs |
| US5712374A (en) | 1995-06-07 | 1998-01-27 | American Cyanamid Company | Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates |
| AU727608B2 (en) * | 1995-10-03 | 2000-12-14 | Scripps Research Institute, The | CBI analogs of CC-1065 and the duocarmycins |
| ATE272058T1 (de) | 1995-10-17 | 2004-08-15 | Combichem Inc | Matrize für die synthese kombinatorischer bibliotheken in lösung |
| JP2000503639A (ja) | 1995-12-22 | 2000-03-28 | ブリストル―マイヤーズ スクイブ カンパニー | 分枝ヒドラゾンのリンカー類 |
| US6143901A (en) | 1996-07-31 | 2000-11-07 | Genesoft, Inc. | Complex formation between dsDNA and pyrrole imidazole polyamides |
| EP0888301B1 (en) * | 1996-03-08 | 2005-08-10 | The Scripps Research Institute | Mcbi analogs of cc-1065 and the duocarmycins |
| WO1997045411A1 (en) * | 1996-05-31 | 1997-12-04 | The Scripps Research Institute | Analogs of cc-1065 and the duocarmycins |
| US6130237A (en) | 1996-09-12 | 2000-10-10 | Cancer Research Campaign Technology Limited | Condensed N-aclyindoles as antitumor agents |
| JPH1087666A (ja) | 1996-09-18 | 1998-04-07 | Kyorin Pharmaceut Co Ltd | デュオカルマイシンｓａ及びその誘導体の製造中間体と製造方法 |
| US6759509B1 (en) | 1996-11-05 | 2004-07-06 | Bristol-Myers Squibb Company | Branched peptide linkers |
| US6329497B1 (en) | 1997-03-28 | 2001-12-11 | The Scripps Research Institute | Sandramycin analogs |
| JP2002510968A (ja) | 1997-05-07 | 2002-04-09 | ブリストル−マイヤーズ スクイブ カンパニー | 組換え抗体−酵素融合タンパク質 |
| JP2002503228A (ja) | 1997-05-22 | 2002-01-29 | ザ スクリップス リサーチ インスティテュート | デュオカルマイシンおよびｃｃ−１０６５の類似体 |
| AU756721B2 (en) | 1997-10-14 | 2003-01-23 | Scripps Research Institute, The | iso-CBI and iso-CI analogs of CC-1065 and the duocarmycins |
| CA2313231A1 (en) * | 1997-12-08 | 1999-06-17 | The Scripps Research Institute | Synthesis of cc-1065/duocarmycin analogs |
| JP3045706B1 (ja) | 1998-09-14 | 2000-05-29 | 科学技術振興事業団 | Ｄｎａの特定塩基配列をアルキル化する化合物及びその合成法 |
| US7425541B2 (en) | 1998-12-11 | 2008-09-16 | Medarex, Inc. | Enzyme-cleavable prodrug compounds |
| US6909006B1 (en) * | 1999-08-27 | 2005-06-21 | Spirogen Limited | Cyclopropylindole derivatives |
| DE60031793T2 (de) | 1999-12-29 | 2007-08-23 | Immunogen Inc., Cambridge | Doxorubicin- und daunorubicin-enthaltende, zytotoxische mittel und deren therapeutische anwendung |
| US6559125B1 (en) * | 2000-01-28 | 2003-05-06 | California Institute Of Technology | Polyamide-alkylator conjugates and related products and method |
| US6555693B2 (en) | 2000-03-16 | 2003-04-29 | Genesoft, Inc. | Charged compounds comprising a nucleic acid binding moiety and uses therefor |
| JP4061819B2 (ja) | 2000-05-12 | 2008-03-19 | 独立行政法人科学技術振興機構 | インターストランドクロスリンク剤の合成方法 |
| JP2004501875A (ja) | 2000-06-14 | 2004-01-22 | メダレックス，インコーポレイティド | トリペプチドプロドラッグ化合物 |
| CA2413149A1 (en) | 2000-06-14 | 2001-12-20 | Medarex, Inc. | Prodrug compounds with isoleucine |
| EP1243276A1 (en) | 2001-03-23 | 2002-09-25 | Franciscus Marinus Hendrikus De Groot | Elongated and multiple spacers containing activatible prodrugs |
| US7256257B2 (en) | 2001-04-30 | 2007-08-14 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
| US20030083263A1 (en) | 2001-04-30 | 2003-05-01 | Svetlana Doronina | Pentapeptide compounds and uses related thereto |
| US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
| MXPA03010961A (es) | 2001-05-31 | 2004-02-27 | Vertex Pharma | Compuestos de tiazol utiles como inhibidores de proteinas cinasas. |
| AU2002303929B9 (en) | 2001-05-31 | 2007-01-25 | E. R. Squibb & Sons, L.L.C. | Cytotoxins, prodrugs, linkers and stabilizers useful therefor |
| ES2364452T3 (es) | 2001-06-11 | 2011-09-02 | Medarex, Inc. | Método para diseñar compuestos profármacos activados por cd10. |
| JP2005502703A (ja) | 2001-09-07 | 2005-01-27 | ザ スクリプス リサーチ インスティテュート | Ｃｃ−１０６５およびデュオカルマイシンのｃｂｉ類似体 |
| US7091186B2 (en) | 2001-09-24 | 2006-08-15 | Seattle Genetics, Inc. | p-Amidobenzylethers in drug delivery agents |
| US6534660B1 (en) * | 2002-04-05 | 2003-03-18 | Immunogen, Inc. | CC-1065 analog synthesis |
| US6756397B2 (en) * | 2002-04-05 | 2004-06-29 | Immunogen, Inc. | Prodrugs of CC-1065 analogs |
| WO2004005326A2 (de) | 2002-07-09 | 2004-01-15 | Morphochem Aktiengellschaft Fu | Tubulysinkonjugate |
| DK1523493T3 (da) | 2002-07-09 | 2013-12-02 | Alexander Doemling | Nye tubulysinanaloge |
| US20050026987A1 (en) | 2003-05-13 | 2005-02-03 | The Scripps Research Institute | CBI analogues of the duocarmycins and CC-1065 |
| JP4806680B2 (ja) * | 2004-05-19 | 2011-11-02 | メダレックス インコーポレイテッド | 自己犠牲リンカー及び薬剤複合体 |
| US7714016B2 (en) * | 2005-04-08 | 2010-05-11 | Medarex, Inc. | Cytotoxic compounds and conjugates with cleavable substrates |
-
2006
- 2006-10-18 JP JP2008538132A patent/JP5116686B2/ja not_active Expired - Fee Related
- 2006-10-18 DK DK06839458.4T patent/DK1940789T3/da active
- 2006-10-18 BR BRPI0619331-5A patent/BRPI0619331A2/pt not_active IP Right Cessation
- 2006-10-18 AU AU2006305842A patent/AU2006305842B2/en not_active Ceased
- 2006-10-18 KR KR1020087011981A patent/KR20080068084A/ko not_active Application Discontinuation
- 2006-10-18 CN CN2006800491755A patent/CN101365679B/zh not_active Expired - Fee Related
- 2006-10-18 SI SI200631269T patent/SI1940789T1/sl unknown
- 2006-10-18 ES ES06839458T patent/ES2375843T3/es active Active
- 2006-10-18 EP EP06839458A patent/EP1940789B1/en active Active
- 2006-10-18 AT AT06839458T patent/ATE534629T1/de active
- 2006-10-18 PL PL06839458T patent/PL1940789T3/pl unknown
- 2006-10-18 PT PT06839458T patent/PT1940789E/pt unknown
- 2006-10-18 RS RS20120009A patent/RS52100B/en unknown
- 2006-10-18 US US12/090,445 patent/US7847105B2/en active Active
- 2006-10-18 EA EA200801176A patent/EA015324B1/ru not_active IP Right Cessation
- 2006-10-18 CA CA2627046A patent/CA2627046C/en not_active Expired - Fee Related
- 2006-10-18 WO PCT/US2006/060050 patent/WO2007051081A1/en active Application Filing
-
2008
- 2008-04-17 IL IL190971A patent/IL190971A/en not_active IP Right Cessation
- 2008-05-15 NO NO20082243A patent/NO20082243L/no not_active Application Discontinuation
- 2008-05-23 ZA ZA200804521A patent/ZA200804521B/xx unknown
- 2008-09-11 HK HK08110088.4A patent/HK1118549A1/xx not_active IP Right Cessation
-
2012
- 2012-01-19 HR HR20120058T patent/HRP20120058T1/hr unknown
- 2012-02-21 CY CY20121100174T patent/CY1112533T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL190971A (en) | 2013-02-28 |
| CA2627046C (en) | 2015-09-15 |
| AU2006305842B2 (en) | 2011-11-03 |
| JP5116686B2 (ja) | 2013-01-09 |
| HK1118549A1 (en) | 2009-02-13 |
| CN101365679B (zh) | 2012-11-14 |
| KR20080068084A (ko) | 2008-07-22 |
| ATE534629T1 (de) | 2011-12-15 |
| EA015324B1 (ru) | 2011-06-30 |
| US7847105B2 (en) | 2010-12-07 |
| BRPI0619331A2 (pt) | 2011-09-27 |
| CY1112533T1 (el) | 2015-12-09 |
| CA2627046A1 (en) | 2007-05-03 |
| JP2009513676A (ja) | 2009-04-02 |
| EP1940789B1 (en) | 2011-11-23 |
| RS52100B (en) | 2012-06-30 |
| ZA200804521B (en) | 2009-04-29 |
| WO2007051081B1 (en) | 2007-07-19 |
| IL190971A0 (en) | 2008-12-29 |
| CN101365679A (zh) | 2009-02-11 |
| NO20082243L (no) | 2008-07-21 |
| PT1940789E (pt) | 2012-02-01 |
| PL1940789T3 (pl) | 2012-04-30 |
| WO2007051081A1 (en) | 2007-05-03 |
| DK1940789T3 (da) | 2012-03-19 |
| ES2375843T3 (es) | 2012-03-06 |
| US20080281102A1 (en) | 2008-11-13 |
| WO2007051081A8 (en) | 2010-12-16 |
| SI1940789T1 (sl) | 2012-03-30 |
| EA200801176A1 (ru) | 2009-02-27 |
| AU2006305842A1 (en) | 2007-05-03 |
| EP1940789A1 (en) | 2008-07-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20120058T1 (hr) | Postupci i spojevi za pripremu analoga cc-1065 | |
| HRP20120071T1 (hr) | (1-AZA-BICIKLO[3.3.1]NON-4-IL)-[5-(1H-INDOL-5-IL)-HETEROARIL]-AMINI KAO KOLINERGIČKI LIGANDI OD N-AChR ZA LIJEČENJE PSIHOTIČKIH I NEURODEGENERATIVNIH POREMEĆAJA | |
| MY140528A (en) | Spiroketal derivatives and their use as therapeutic agents for diabetes | |
| HRP20050390A2 (en) | Substituted benzoxazinones and uses thereof | |
| RS51007B (sr) | Supstituisani piridinil i pirimidinil derivati kao modulatori metabolizma i lečenje poremećaja proisteklih iz toga | |
| PE20070751A1 (es) | Derivados de isoxazolidina como inhibidores de la interaccion de proteinas bcl | |
| HRP20030565B1 (hr) | Nukleozid derivati kao inhibitori rna-ovisne rna virusne polimeraze | |
| MY144718A (en) | Viral polymerase inhibitors. | |
| RS49684B (sr) | Upotreba derivata 7-(2-oksa-5,8- diazabiciklo[4.3.0]non-8-il)-hinolon- karbonske kiseline i nafthiridonkarbonske kiseline za pripremanje leka za terapiju helikobakter-pilori infekcija i sa time povezanim gastroduodenalnim oboljenjima | |
| NO20074071L (no) | Hydrazinometyl, hydrozonometyl og 5-leddete heterocykliske forbindelser som virker som MTOR inhibitorer og anvendelse derav som anti-cancer midler | |
| AR074862A1 (es) | Derivados de heterociclo biciclicos y sus metodos de uso | |
| IL179171A (en) | Inodolo [b – 3,2] Process for the preparation of quinoxylins converted into alkyl, and pharmaceutical preparations containing them | |
| HRP20050775A2 (en) | Quinolinone/benzoxazinone derivatives and uses thereof | |
| BRPI0619894B8 (pt) | composto de amina e composição farmacêutica | |
| MX2009003927A (es) | Derivado espirocetal de tioglucosa y uso del mismo como un agente terapeutico para la diabetes. | |
| HUP0203288A2 (hu) | Foszfodiészteráz VII inhibitor hatású pirrolszármazékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| UA95223C2 (ru) | Производные пиридопиримидина, их получение, их применение в терапии | |
| HRP20130918T1 (hr) | Derivati 4-aminopirimidina kao receptori antagonista histamina h4 | |
| MY142304A (en) | Novel pyrimidine nucleoside compound or salt thereof | |
| RS97004A (en) | Benzoxazine derivatives as 5-ht6 modulators and uses thereof | |
| RS20050450A (en) | 2-aminocarbonyl-quinoline compounds as platelet adenosine diphosphate receptor antagonists | |
| HUP0402500A2 (hu) | Gyulladáskeltő citokinok kibocsátását gátló heterokondenzált pirazol-3-on vegyületek és az ezeket tartalmazó gyógyszerkészítmények | |
| RS51557B (en) | 4H-1,2,4-TRIAZIN-5-ONE DERIVATIVES, THEIR PRODUCTION AND THEIR USE AS ALFA 7 NICOTINE ACETYLHOLINE RECEPTORS | |
| IL206269A (en) | Synthesis of biguanidines and triazines and complexes of biguanidino-aluminum as intermediates | |
| HRP20080119T3 (hr) | Derivati benzotiadizina, postupak njihove priprave i farmaceutske smjese koje ih sadrže |